CSF amyloid‐beta, tau, and neurodegenerative and inflammatory biomarkers in cognitively unimpaired late middle‐aged and older adult <i>APOE ε4</i> homozygotes, heterozygotes, and non‐carriers from the Arizona APOE Cohort

Valentina Ghisays,Willemijn J. Jansen,Yinghua Chen,Hillary D. Protas,Michael H. Malek‐Ahmadi,Ji Luo,Wendy Lee,Kewei Chen,Yi Su,Richard J. Caselli,Henrik Zetterberg,Kaj Blennow,Eric M. Reiman
DOI: https://doi.org/10.1002/alz.057242
2021-01-01
Abstract:Background APOE4 gene dose, the number of apolipoprotein E ‐ɛ4 (APOE4) ɛ4 alleles in a person’s genotype, is associated with higher Alzheimer’s disease (AD) risk and younger median age at dementia onset. We previously found relationships between PET, plasma, and CSF measurements of amyloid‐β (Aβ) pathophysiology in APOE4 gene dose. Here, we characterize the core AD CSF biomarkers (Aβ 42/40 , pTau 181 , tTau), the neurodegeneration marker neurofilament light chain (NfL) and the glial biomarkers soluble TREM2 (sTREM2), and glial fibrillary acidic protein (GFAP) measurements in age‐matched 48‐70 year‐old cognitively unimpaired (CU) APOE4 homozygotes (HMs), heterozygotes (HTs) and non‐carriers (NCs) from the Arizona cohort. Method CSF biomarker measurements were performed at the University of Gothenburg using Lumipulse and ELISA immunoassays. CSF biomarker measurements were characterized and compared using linear‐tend ANOVAs in 12 HMs, 17 HTs, and 20 NCs who were CU, 48‐70 years old and did not differ significantly in their age, sex, or educational level. Result As expected, CSF Aβ 42/40 ratios were inversely associated with APOE4 gene dose (linear trend, HMHT>NC p<0.05). Non‐significant trends suggested that CSF sTREM2 and sTREM2/pTau 181 measurements were inversely associated with APOE4 gene dose (HM
What problem does this paper attempt to address?